A Phase I Open and Multiple Ascending Dose Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamic Characteristics of XY0206 in Subjects With Chinese Advanced or Metastatic Solid Tumours
Latest Information Update: 04 Aug 2022
At a glance
- Drugs XY-0206 (Primary)
- Indications Gastrointestinal cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Shijiazhuang Yiling Pharmaceutical
- 19 Aug 2020 Status changed from not yet recruiting to recruiting.
- 12 Sep 2018 New trial record